SLTM Inhibitors
SLTM inhibitors pertain to a class of chemical compounds that specifically target and impede the activity of a particular enzyme or molecular pathway known as SLTM. The acronym SLTM typically represents a specific protein or enzyme that plays a crucial role in a biochemical process within an organism. Inhibitors, by definition, are molecules that bind to enzymes and decrease their activity. By binding to the active site or another site (allosteric site) on the enzyme, these inhibitors can cause changes in the enzyme's structure, rendering it less effective or entirely inactive at catalyzing its specific biochemical reaction. The resulting inhibition can be either reversible or irreversible, depending on the nature of the interaction between the inhibitor and the enzyme.
The design and development of SLTM inhibitors involve a deep understanding of the enzyme's structure and the molecular dynamics that govern its interaction with substrates and other molecules. This process often begins with the identification of the enzyme's active site and the key amino acids that are involved in substrate binding and catalysis. Once these critical areas are identified, chemical compounds are either screened or rationally designed to interact with these sites in a way that prevents the enzyme from performing its normal function. The specificity of SLTM inhibitors is of paramount importance, as off-target effects can lead to the disruption of other physiological processes. Researchers often use a combination of computational modeling and empirical testing to refine these compounds, ensuring that they exhibit a high affinity for the SLTM enzyme and a low affinity for other proteins. The molecular interaction can range from hydrogen bonding and ionic interactions to more complex van der Waals forces and hydrophobic effects, all of which contribute to the inhibitor's efficacy and specificity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphatidylinositol 3-kinases (PI3K), which are upstream of many signaling pathways. LY294002 inhibits PI3K activity, which can prevent the phosphorylation and activation of downstream targets such as AKT. As SLTM is known to interact with phosphorylated forms of certain proteins, the inhibition of this pathway can lead to reduced SLTM functional activity due to lack of interaction with its phosphorylated partners. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent PI3K inhibitor that irreversibly binds to the catalytic site of PI3K, leading to the inhibition of downstream signaling pathways including AKT. This reduction in AKT activity would result in a decreased regulation of proteins that interact with SLTM, thus indirectly decreasing SLTM activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that binds to the FKBP12 and inhibits the mTORC1 complex, which is involved in protein synthesis and cell growth. By inhibiting mTORC1, rapamycin can reduce the synthesis of proteins that may be essential for SLTM interaction and function, leading to an indirect inhibition of SLTM activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK1/2 inhibitor that blocks the MAPK/ERK pathway, which is involved in cell proliferation and differentiation. By inhibiting MEK1/2, U0126 can prevent the activation of ERK1/2 and their downstream effectors, potentially reducing the levels or modifying the state of proteins that SLTM would normally interact with. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
A p38 MAPK inhibitor that blocks the p38 signaling pathway, which is involved in stress responses and cytokine production. Inhibition of p38 MAPK can lead to altered cellular responses that could indirectly affect SLTM interaction with stress-related proteins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. PD98059 prevents the activation of ERK, thereby potentially altering the phosphorylation state or availability of proteins that interact with SLTM. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK family and is involved in apoptosis and cell differentiation. By inhibiting JNK activity, SP600125 can disrupt the phosphorylation of target proteins that might be crucial for SLTM function. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $220.00 $378.00 | 5 | |
A selective inhibitor of MEK5, which specifically inhibits the ERK5 pathway. This pathway is involved in various cellular processes including proliferation and differentiation. By inhibiting MEK5, BIX 02189 could affect the cellular context in which SLTM operates, leading to its functional inhibition. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A protein kinase C (PKC) inhibitor that affects various cellular processes by inhibiting PKC isoforms. Since PKC can phosphorylate a wide range of substrates, Gö 6983 can prevent the phosphorylation of proteins that may be required for SLTM's activity or interaction with other molecules. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
An inhibitor of BMP signaling which blocks the activity of BMP type I receptors. Since BMP signaling can influence a variety of cellular processes and protein interactions, inhibition by dorsomorphin could indirectly affect the functional activity of SLTM by altering its protein interaction network. | ||||||